Description
Indication & Scope
Technetium Tc 99m Rectegatide Pecixetan Injection provides auxiliary imaging examination for suspected regional lymph node metastasis in patients diagnosed with lung cancer, to assist clinicians in judging tumor lymphatic spread range before surgical resection.
- Mechanism: This radiotracer is labeled with metastable technetium-99m radioisotope conjugated with Rectega peptide ligand. After intravenous injection, the peptide specifically accumulates in lung cancer metastatic regional lymph nodes. Gamma rays released by 99mTc can be captured by nuclear medicine imaging equipment to display lymph node lesion distribution and metastasis status. The radionuclide has a short 6-hour physical half-life to minimize long-term radiation exposure to patients.
- Drug class: Radioactive diagnostic radiopharmaceutical; tumor lymph node imaging tracer.
- Clinical use: Preoperative staging auxiliary imaging for suspected lung cancer patients, precisely locating regional lymph node metastasis lesions, guiding accurate surgical lymph node dissection scope, avoiding under-treatment or excessive lymph node resection.
| Generic Name | Technetium Tc 99m Rectegatide Pecixetan Injection |
| Brand Name | – |
| Ingredient | Technetium Tc 99m Rectegatide Pecixetan |
| Dosage Form | Injection |
| Package | 740MBq/ml to 2035 MBq/ml (according to the indicated time) |
| Conditions Treated | Suspected lung cancer patients requiring auxiliary radiological assessment of regional lymph node metastatic status before surgical intervention |
| Taboos | Pregnant women; breastfeeding women (must suspend breastfeeding for 24 hours post-injection); patients with severe hypersensitivity to peptide tracers or technetium radiopharmaceutical excipients |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Sealed vials must be stored in shielded radioactive lead containers at controlled room temperature 20°C–25°C, away from public living areas, strictly follow national radioactive substance management regulations. The prepared injection must be used within 24 hours after radionuclide elution |
| Manufacturer | Foshan RuiDiAo Pharmaceutical, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20260016 |
| Approval Date | Mar 31, 2026 |
| Shelf Life | 12 months |
How to use ?
Recommended Dose: Intravenous single injection of calibrated radioactive activity adjusted according to patient body weight, standard diagnostic activity range 100–200 MBq for adult lung cancer patients.
Time: Inject the radiotracer intravenously 1–2 hours before scheduled nuclear medicine lymph node imaging scan to allow sufficient tracer accumulation in target lymph nodes.
Instructions for use: Only certified nuclear medicine medical staff can complete injection and imaging operations. All unused residual radioactive liquid must be disposed of via standard radioactive waste treatment channels. Patients need to drink large volumes of water after scanning to accelerate radionuclide excretion from urine. Isolate from pregnant women and infants for 24 hours post-administration. Do not inject intrathecally or subcutaneously.
Interaction: No chemical interaction with other contrast media or anti-cancer drugs. Patients receiving iodine CT contrast agents need a minimum 72-hour interval before or after this radiotracer scan to avoid imaging interference.
Side effects: Extremely rare mild adverse reactions: transient slight injection-site flushing, mild headache within 1 hour after injection. Severe adverse reactions such as radiotoxicity or severe allergy are rarely reported under standard dose.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is Technetium Tc 99m Rectegatide Pecixetan Injection used to check for lung cancer patients?
It helps doctors clearly see if your lung cancer has spread to nearby lymph nodes before lung surgery, guiding precise surgical plans.
Are pregnant women allowed to receive Technetium Tc 99m Rectegatide Pecixetan Injection scan?
No, pregnant patients are completely contraindicated due to potential fetal radiation risks, breastfeeding mothers must stop nursing for one full day after injection.
How long after using Technetium Tc 99m Rectegatide Pecixetan Injection does patients need to wait before finishing the lymph node imaging scan?
Patients will receive the intravenous injection 1 to 2 hours in advance of your scheduled nuclear medicine scan to let the tracer gather in target lymph nodes.
Can Technetium Tc 99m Rectegatide Pecixetan Injection be stored at home like regular medicines?
Absolutely not, this radioactive drug must be locked inside lead shielding containers in hospital nuclear medicine departments following official radiation safety rules.
Technetium Tc 99m Rectegatide Pecixetan Injection | Lung Cancer Examination | DengYueRX
INN: Technetium Tc 99m Rectegatide Pecixetan Injection
Indications: Lung cancer examination
Dosage Form: Injection
Strength: 740MBq/ml to 2035 MBq/ml (according to the indicated time)
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
